Search

CN-120131649-B - Application of wocelotor in preparation of preparation for inhibiting influenza virus

CN120131649BCN 120131649 BCN120131649 BCN 120131649BCN-120131649-B

Abstract

The use of Wo Sailuo torr in the manufacture of a formulation for use alone or in combination with other formulations to prevent influenza, treat influenza, slow influenza or inhibit influenza virus proliferation is disclosed. Wo Sailuo Torr and the composition containing the Vortioxetol have good safety, can well inhibit the proliferation of influenza virus, and have application prospects in treating influenza.

Inventors

  • LI CHENGJUN
  • CHEN HUALAN
  • JIANG LI
  • WANG GUANGWEN
  • DENG GUOHUA
  • SHI JIANZHONG

Assignees

  • 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心）

Dates

Publication Date
20260508
Application Date
20250324

Claims (6)

  1. 1. A pharmaceutical composition for inhibiting influenza virus, the pharmaceutically active ingredient of the pharmaceutical composition comprising an active substance a and an active substance b; the active substance a is any one or the combination of two of Wo Sailuo torr and Wo Sailuo torr of medicinal salts; the active substance b is any one or the combination of two of epalrestat and epalrestat medicinal salt; the Wo Sailuo support has the structural formula: ; The structural formula of epalrestat is as follows: ; the molar ratio of the active substance a to the active substance b is 1:0.3-0.5.
  2. 2. The pharmaceutical composition of claim 1, wherein the composition further comprises an adjuvant.
  3. 3. Use of a biological material for the preparation of a medicament for improving health; The biological material is the pharmaceutical composition or active substance a according to claim 1 or 2; the active substance a is any one or the combination of two of Wo Sailuo torr or Wo Sailuo torr medicinal salts; the Wo Sailuo support has the structural formula: ; the use is selected from any one or a combination of the following U1, U2, U3 and U4; U1, the health condition improvement is prevention of influenza, treatment of influenza, slowing of influenza or inhibition of influenza virus proliferation; U2, the health condition is improved by reducing the damage of influenza virus to the lung; U3, the health condition is improved by inhibiting RNA polymerase of influenza virus to reduce the damage of the influenza virus to the organism; and U4, the health condition is improved by inhibiting influenza virus neuraminidase to reduce the damage of influenza virus to organisms.
  4. 4. The use according to claim 3, wherein the influenza virus is an influenza a virus and the influenza is an influenza a.
  5. 5. The use according to claim 3, wherein the influenza virus is an H1N1 influenza virus and the influenza is an influenza caused by an H1N1 influenza virus.
  6. 6. The use according to claim 3, wherein the influenza is selected from the group consisting of human influenza, avian influenza, swine influenza.

Description

Application of wocelotor in preparation of preparation for inhibiting influenza virus Technical Field The invention belongs to the field of pharmacy, and relates to application of wocelotor in preparation of a preparation for inhibiting influenza virus. Background Influenza virus (Influenza virus) is a representative virus of the Orthomyxoviridae family, and is divided into four genera, a (a), B (B), C (C) and D (D), wherein Influenza a, B and C viruses all infect humans. From WHO statistics, 5% to 10% of adults and 20% to 30% of children are expected to be infected with influenza each year, resulting in 300 to 500 tens of thousands of severe cases and about 100 tens of thousands of deaths worldwide. Influenza a virus (Influenza A virus, IAV), which is an economically and public health important respiratory pathogen because of its high incidence of severe morbidity and mortality, has a viral genome consisting of 8 segmented single-stranded negative strand RNAs encoding 10 essential proteins including PB2, PB1, PA, HA, NP, NA, M1, M2, NS1, NEP/NS2 and a variety of non-essential accessory proteins such as PB1-F2, PA-X, etc. Seasonal influenza a viruses are typically two subtypes of H1N1 and H3N2, which have caused repeated epidemics of varying severity for decades. In the united states, influenza causes over 20 tens of thousands of hospitalizations each year, with 3000 to 49000 deaths each year in non-epidemic seasons. Because of their frequent occurrence of antigenic drift and conversion, novel strains from other species lead to human influenza pandemics, such as "swine influenza" H1N1 and avian influenza H5N1 in 2009. Since humans have little immunity to them, they can rapidly spread worldwide, posing a significant threat to global health. Influenza virus is one of the main threats of global public health safety, and vaccines achieve good effects in prevention and control of animal influenza, but the prevention and control of human influenza has no remarkable effect due to the problems of low vaccination proportion, high virus variation rate, different vaccine protection force and the like. Drugs are another important tool for controlling human influenza, and drugs that have been currently entered into the clinic for treating influenza virus infection can be classified into a first generation M2 ion channel inhibitor, a second generation neuraminidase inhibitor (Neuraminidase inhibitors, NAI) and a third generation cap-dependent endonuclease inhibitor. Influenza viruses, which are RNA viruses with high mutation rates, have evolved rapidly into multiple drug-resistant strains under high pressure screening of drugs since the advent of the generation of anti-influenza drugs to over five decades. Among the epidemic strains, existing drug-resistant strains have taken up a considerable proportion. In view of the limitations of human influenza virus vaccine application and the rapid generation of drug resistance, the necessity of screening novel influenza virus small molecule inhibitors is increasingly highlighted. Triptolide, namely PG 492, NSC 165677, english Triptonide, with CAS number 38647-11-9, and Wnt signal inhibitor as conventional active application, and has the following molecular structural formula: the buquinate, the alias Bipenquinate, NSC 368390, DUP785, english Brequinar, CAS number 96187-53-0, has the general active application of being a powerful inhibitor of dihydroorotate dehydrogenase, has powerful activity on broad-spectrum viruses and has the following molecular structural formula: Wo Sailuo Torr, alias GBT 440, english voxelotor, CAS number 1446321-46-5, a conventional active use is a sickle hemoglobin (HbS) polymerization inhibitor, the molecular structural formula is as follows: Mizoribine, alias Bredinin, NSC 289637, HE 69, english Mizoribine, CAS number 50924-49-7, the general active use is immunosuppressant, the molecular structural formula is as follows: Epalrestat, alias ONO2235, epalrestat, english EPALRESTAT, CAS No. 82159-09-9, is conventionally active as an aldose reductase inhibitor, and is effective in improving symptoms associated with diabetic neuropathy and in slowing the progression of the disease. The molecular structural formula is as follows: no report on the application of the medicines in treating influenza is seen. Disclosure of Invention In order to solve the problems existing in the prior art, a first aspect of the present invention provides a pharmaceutical composition, the pharmaceutically active ingredient of which comprises an active substance a and an active substance b; The active substance a is any one of a Wo Sailuo torr, a Wo Sailuo torr medicinal salt and a Wo Sailuo torr prodrug, a combination of any two or a combination of three; the active substance b is any one of epalrestat, epalrestat medicinal salt and epalrestat prodrug, any two or three combinations; the Wo Sailuo support has the structural formula: ; The structural formula of epalrestat is as fol